Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.

[1]  Steven P Jones,et al.  Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia. , 2008, American journal of physiology. Heart and circulatory physiology.

[2]  L. Huang,et al.  Carrot and stick: HIF-α engages c-Myc in hypoxic adaptation , 2008, Cell Death and Differentiation.

[3]  R. Bartrons,et al.  Characterization of a new liver- and kidney-specific pfkfb3 isozyme that is downregulated by cell proliferation and dedifferentiation. , 2008, Biochemical and Biophysical Research Communications - BBRC.

[4]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[5]  Jaime Caro,et al.  Hypoxia, glucose metabolism and the Warburg’s effect , 2007, Journal of bioenergetics and biomembranes.

[6]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[7]  A. Lane,et al.  Ras transformation requires metabolic control by 6-phosphofructo-2-kinase , 2006, Oncogene.

[8]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[9]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[10]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[11]  R. Bartrons,et al.  PFKFB3 gene silencing decreases glycolysis, induces cell‐cycle delay and inhibits anchorage‐independent growth in HeLa cells , 2006, FEBS letters.

[12]  M. López-Lázaro.  HIF‐1: hypoxia‐inducible factor or dysoxia‐inducible factor? , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  D. Rigden,et al.  Evolutionary analysis of fructose 2,6‐bisphosphate metabolism , 2006, IUBMB life.

[14]  Yong-Hwan Lee,et al.  Crystal Structure of the Hypoxia-inducible Form of 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) , 2006, Journal of Biological Chemistry.

[15]  B. Sharma,et al.  PET/CT in oncology--a major advance. , 2005, Clinical radiology.

[16]  Marta Cascante,et al.  K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts , 2005 .

[17]  A. Yalçin,et al.  Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality. , 2005, Biochemical and biophysical research communications.

[18]  S. Schreiber,et al.  Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Gillies,et al.  Hypoxia-Inducible Factor-1α and the Glycolytic Phenotype in Tumors , 2005 .

[20]  N. Amariglio,et al.  Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. , 2005, Cancer research.

[21]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[22]  David Beach,et al.  Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.

[23]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[24]  D. Vertommen,et al.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. , 2004, The Biochemical journal.

[25]  P. Hammerman,et al.  Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  J. Caro,et al.  Hypoxic regulation of the 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase gene family (PFKFB‐1–4) expression in vivo , 2003, FEBS letters.

[27]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[28]  J. L. Rosa,et al.  Regulation of ubiquitous 6‐phosphofructo‐2‐kinase by the ubiquitin‐proteasome proteolytic pathway during myogenic C2C12 cell differentiation , 2003, FEBS letters.

[29]  L. Leng,et al.  High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. , 2002, Cancer research.

[30]  L. Bertrand,et al.  Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. , 2002, Journal of molecular and cellular cardiology.

[31]  L. Bertrand,et al.  The Stimulation of Glycolysis by Hypoxia in Activated Monocytes Is Mediated by AMP-activated Protein Kinase and Inducible 6-Phosphofructo-2-kinase* , 2002, The Journal of Biological Chemistry.

[32]  R. Bartrons,et al.  Insulin induces PFKFB3 gene expression in HT29 human colon adenocarcinoma cells. , 2002, Biochimica et biophysica acta.

[33]  N. Sang,et al.  Hypoxia-inducible Factor-1-mediated Expression of the 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) Gene , 2002, The Journal of Biological Chemistry.

[34]  W. Zwerschke,et al.  Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7 , 2001, Oncogene.

[35]  M Cascante,et al.  Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. , 2001, The Journal of biological chemistry.

[36]  T. Hunter,et al.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[37]  K. Eschrich,et al.  Splice isoforms of ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in human brain. , 2001, Brain research. Molecular brain research.

[38]  J. L. Rosa,et al.  The human ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene (PFKFB3): promoter characterization and genomic structure. , 2001, Gene.

[39]  L. Boros,et al.  Genistein Inhibits Nonoxidative Ribose Synthesis in MIA Pancreatic Adenocarcinoma Cells: A New Mechanism of Controlling Tumor Growth , 2001, Pancreas.

[40]  C. Dang,et al.  Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.

[41]  M. Cascante,et al.  Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. , 2000, Cancer research.

[42]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[43]  E. Furuya,et al.  Tissue‐specific alternative splicing of rat brain fructose 6‐phosphate 2‐kinase/fructose 2,6‐bisphosphatase , 1999, FEBS letters.

[44]  C. Paraskeva,et al.  An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis , 1999, Oncogene.

[45]  R. Sakakibara,et al.  Tissue distribution of placenta-type 6-phosphofructo- 2-kinase/fructose-2,6-bisphosphatase. , 1999, Biochemical and biophysical research communications.

[46]  R. Bucala,et al.  An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  X. Estivill,et al.  Molecular cloning, expression, and chromosomal localization of a ubiquitously expressed human 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase gene (PFKFB3) , 1999, Cytogenetic and Genome Research.

[48]  C. Dang,et al.  A unique glucose-dependent apoptotic pathway induced by c-Myc. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Sakakibara,et al.  Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. , 1997, Journal of biochemistry.

[50]  Akiko Sakai,et al.  Novel Isoforms of Rat Brain Fructose 6‐Phosphate 2‐Kinase/Fructose 2,6‐Bisphosphatase Are Generated by Tissue‐Specific Alternative Splicing , 1997, Journal of neurochemistry.

[51]  C. Sánchez-Martínez,et al.  Analysis of phosphofructokinase subunits and isozymes in ascites tumor cells and its original tissue, murine mammary gland , 1997, FEBS letters.

[52]  J. A. Hamilton,et al.  Identification of PRG1, a novel progestin-responsive gene with sequence homology to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. , 1997, Molecular endocrinology.

[53]  R. Sakakibara,et al.  Cloning of cDNA encoding for a novel isozyme of fructose 6-phosphate, 2-kinase/fructose 2,6-bisphosphatase from human placenta. , 1996, Journal of biochemistry.

[54]  L. Hue,et al.  Activation of 6-phosphofructo-2-kinase by pp60v-src is an indirect effect. , 1992, The Biochemical journal.

[55]  H. Kole,et al.  Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. , 1991, Archives of biochemistry and biophysics.

[56]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[57]  C. V. van Veelen,et al.  Subunit composition, regulatory properties, and phosphorylation of phosphofructokinase from human gliomas. , 1987, Cancer research.

[58]  D. Colomer,et al.  Control of phosphofructokinase by fructose 2,6-bisphosphate in B-lymphocytes and B-chronic lymphocytic leukemia cells. , 1987, Cancer research.

[59]  J. Ghysdael,et al.  Expression of the v-src or v-fps oncogene increases fructose 2,6-bisphosphate in chick-embryo fibroblasts. Novel mechanism for the stimulation of glycolysis by retroviruses. , 1986, The Biochemical journal.

[60]  D. Knowles,et al.  Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy. , 1985, Cancer research.

[61]  H. Hers.  The discovery and the biological role of fructose 2,6-bisphosphate. , 1984, Biochemical Society transactions.

[62]  E. Schaftingen,et al.  Fructose 2,6-bisphosphate. , 1982, Biochemical Society Transactions.

[63]  E. Schaftingen,et al.  Control of liver 6-phosphofructokinase by fructose 2,6-bisphosphate and other effectors. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[64]  E. Schaftingen,et al.  Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. , 1980, The Biochemical journal.

[65]  E. Schaftingen,et al.  Control of the fructose-6-phosphate/fructose 1,6-bisphosphate cycle in isolated hepatocytes by glucose and glucagon. Role of a low-molecular-weight stimulator of phosphofructokinase. , 1980, The Biochemical journal.

[66]  D. Goldberg,et al.  Enzymes of glucose metabolism in carcinoma of the cervix and endometrium of the human uterus. , 1978, British Journal of Cancer.

[67]  G. Weber.  Enzymology of cancer cells (second of two parts). , 1977, The New England journal of medicine.

[68]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[69]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[70]  S. Khan,et al.  Roles for fructose-2,6-bisphosphate in the control of fuel metabolism: beyond its allosteric effects on glycolytic and gluconeogenic enzymes. , 2006, Advances in enzyme regulation.

[71]  Chaodong Wu,et al.  Regulation of the regulatory enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. , 2004, Advances in enzyme regulation.

[72]  R. Bartrons,et al.  PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. , 2001, Trends in biochemical sciences.

[73]  Z. Ronai,et al.  K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. , 2000, Cancer detection and prevention.

[74]  A. Lange,et al.  Fructose‐2,6‐bisphosphate and control of carbohydrate metabolism in eukaryotes , 1999, BioFactors.

[75]  L. Hue,et al.  Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes. , 1993, Advances in enzyme regulation.

[76]  S. Mango,et al.  cis-acting determinants of c-myc mRNA stability. , 1990, Enzyme.

[77]  B. V. van Oirschot,et al.  Glycolytic enzyme activities in breast cancer metastases. , 1988, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[78]  B. V. van Oirschot,et al.  Glycolytic enzymes in breast cancer, benign breast disease and normal breast tissue. , 1987, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.